We believe the prevention of infection-related adverse pregnancy outcome is the most important focus for obstetricians today. An emphasis upon immunization of susceptible women, prevention of transmissible disease by modification of patient behavior, and identification and treatment of silent infections should become standards of practice. This will require educational initiatives for physicians and their patients as well as continued clinical trials to determine costs and effectiveness.
It requires a change in practice priorities. As a specialty, we have focused upon operative skills plus the recognition and treatment of disease. Moving our priorities forward to prevention will be difficult because it represents an abrupt change in care. What are our standards today? In middle class America, the newly sexually active teenager switches her physician provider from the pediatrician to the obstetrician. Currently, the screening for this young woman is a Papanicolaou (Pap) smear and prevention is limited to a prescription for an oral contraceptive. This protects against an unwanted pregnancy, but offers no protection against sexually transmitted diseases. For urban poor women, no preventive care is available. The focus is on pathology. We treat urban poor teenagers with an unwanted pregnancy or symptomatic pelvic inflammatory disease. This is a narrow and unacceptable scope of practice.
An outline for infection-related adverse pregnancy outcomes has been the mnemonic TORCH, in which the significant pathogens for the fetus have been identified. We would like to expand this to STORCH s for the purposes of this discussion of prevention (see Table 1 ). The focus will be directed toward three strategies of prevention: vaccine administration, preventive counseling to achieve maternal behavior modification, and treatment of silent infections. All of these strategies require the use of screening laboratory studies to determine the risks in asymptomatic patients. This requires, on the part of the obstetrician, knowledge and understanding of laboratory studies, many of which are new. Table 2 ). s A similar preventive program in Belgium has significantly reduced maternal acquisition of toxoplasmosis during pregnancy. 
VACCINES

Cytomegalovirus (CMV)
CMV presents a different set of circumstances. It is a much more common infection and most authorities think it is the most frequent pathogen involved in newborn morbidity. A recent publication from the Centers for Disease Control (CDC) estimated that 30,000-40,000 infants are infected each year with CMV and 9,000 of these infants suffer permanent sequelae. 6 Other evaluations indicate that the most frequent and serious newborn infections occur in susceptible women who acquire their first infection during pregnancy. 17 The presence of antibody offers protection to the newborn. American obstetricians have not offered screening for CMV because no effective antiviral therapy has surfaced. This is a short-sighted approach. Antibody screening should be done in pregnant women to determine susceptibility. If susceptible, the pregnant women should have three options presented to her (see Table 3 ). s For this virus, there are a wide variety of risks. CMV is a sexually transmitted disease. A sexually active pregnant woman who is not in a monogamous relationship should require her male sexual partner to wear a condom. This requires attitudinal changes by both the obstetrician and the pregnant woman. The condom in this situation is not to prevent pregnancy, but to lower the risk of acquiring a sexually transmitted disease. Small children in a group setting such as a day care center are frequently infected with CMV and are asymptomatic. 18 They shed large amounts of virus their saliva and urine. Susceptible women should avoid "sloppy" kisses with these children and should wash their hands if they have to change a diaper. Finally, for the rare occasions when a susceptible pregnant woman needs a blood transfusion, the donated blood should be CMV antibody negative. If this is not possible, leukocyte depleted blood should be given to lower the risk of CMV acquisition. 19 None of these preventive measures should be difficult to institute. 4 These culture-positive women should be treated prior to delivery.
Group B Streptococcus
The group B streptococcus is a feared organism by obstetricians. Vaginal colonization with this organism which causes no maternal symptomatology can result in vertical transmission to the fetus with newborn sepsis and death despite newborn antibiotic treatment. 41 There is evidence that treatment of the mother with antibiotics prior to delivery markedly reduces newborn infectious morbidity and mortality. 42 The problem with any strategy of antibiotic prophylaxis is the selection of the mother at risk for newborn group B streptococcal infection. 47 There are two major reasons for this. This antibiotic intervention has not proved successful in lowering the premature delivery rate 48 and systemic antibiotic treatment has not been effective in the persistent eradication of the group B streptococcus from the vagina of these women. 49 Finally, there is the question of the selection of pregnant women to receive antibiotic prophylaxis in labor. The CDC has suggested two strategies for the patient who is not penicillin allergic; they recommend penicillin G with ampicillin as an alternative, s There is controversy surrounding both of these choices. Penicillin G has a narrow range of antibacterial activity. For the obstetrician concerned about other organisms which cause newborn infection with some frequency such as Escherichia coli, Hemophilus influenzae, Listeria monocytogenes, Ureaplasma urealyticum, and C. trachomatis are not covered. On the positive side, widespread use of this narrow spectrum antibiotic should not have a major impact on the bacterial flora found on a labor and delivery floor. Many obstetricians favor ampicillin, because its wider spectrum of activity means that some strains of E. co/i, H. influenzae, and L. monocytogenes will be covered as well as the group B streptococcus. This widespread use of a broader spectrum antibiotic has a cost. There will be a greater impact upon the antibiotic flora of an obstetrical service and there already has been one report of an increase in the number of gram-negative aerobic infections in the newborn when this ampicillin prophylaxis was employed, sl There are important considerations to be kept in mind when a preventive regimen is proposed. All antibiotic intervention regimens have the capability of lowering the incidence of group B streptococcal disease, s2 All are different in their technique of selecting mothers at risk (see Table 4) and none is 100% successful in preventing group B streptococcal newborn disease, s2 Intrapartum antibiotic administration to the mother will not prevent all cases. There have been instances in which mothers given antibiotics when they were admitted in labor still have delivered infants with group B sepsis and death due to this infection, s's2
All of this is prologue to the current CDC rec- s9 The difficulty is that the majority of pregnant women are colonized with this organism 6 so the problem of determining which newborn of these colonized women will be at risk remains un- solved. This organism has the potential to cause problems. It can occasionally be isolated from the amniotic fluid of women in premature labor. 61 In evaluating the pregnancy history of newborns who become infected, the route of delivery did not alter the risk of infection, but chorioamnionitis did. 6z The antibiotic of choice in the past has been erythromycin, but administration of this drug to pregnant women was ineffective in reducing the number of women who remained vaginal culture positive for this organism. 6 Clearly, more studies will be needed to delineate risk factors.
